Kenneth F. Grossmann

Also affiliated with Huntsman Cancer Institute, Providence Portland Medical Center, Cancer Research Center

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 16 papers. Top paper: “Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma”.

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

New England Journal of Medicine(2023)10.1056/nejmoa2211437

N/A

6.5DataRank · unranked

846 citations

Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John Hyngstrom +48 more

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

Nature Medicine(2023)10.1038/s41591-023-02498-y

N/A

4.8DataRank · unranked

171 citations

Shay Bellasea, Kari Kendra, Nikhil I. Khushalani, Katie M. Campbell, Philip O. Scumpia +28 more

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

New England Journal of Medicine(2015)10.1056/nejmoa1504030

N/A

1.3DataRank · unranked

8085 citations

Vanna Chiarion-Sileni, Rene Gonzalez, Jean Jacques Grob, C. Lance Cowey, Christopher D. Lao +35 more

Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9501

N/A

1.3DataRank · unranked

18 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Teresa M. Petrella +15 more

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Cancer Discovery(2021)10.1158/2159-8290.cd-21-1141

N/A

0DataRank · unranked

102 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2020-001781

N/A

0DataRank · unranked

35 citations

Jordan P. McPherson, Benjamin Haaland, Kenneth F. Grossmann, Carolyn Luckett, Benjamin Newell Voorhies +6 more

S1801: A randomized trial of adjuvant versus neoadjuvant pembrolizumab for melanoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps9585

N/A

0DataRank · unranked

3 citations

Megan Othus, James Moon, Michael T. Tetzlaff, Elizabeth I. Buchbinder, Vernon K. Sondak +9 more

Granulomatous and sarcoid-like immune related adverse events (irAEs) in melanoma patients following CTLA4 blockade adjuvant therapy: An analysis of 1670 high-risk patients.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9582

N/A

0DataRank · unranked

1 citations

Ibrahim Yassine, Sandra J. Lee, Megan Othus, James Moon, John M. Kirkwood +5 more

1073P Quality of life (QOL) endpoints from the phase III intergroup S1404 adjuvant melanoma trial

Annals of Oncology(2021)10.1016/j.annonc.2021.08.1458

N/A

0DataRank · unranked

0 citations

Joseph M. Unger, Megan Othus, Amy K. Darke, Ahmad A. Tarhini, John M. Kirkwood +5 more

Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9502

N/A

0DataRank · unranked

21 citations

James Moon, Zeynep Eroglu, Siwen Hu‐Lieskovan, William E. Carson, David A. Wada +15 more

Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review

Cancers(2023)10.3390/cancers15092561

N/A

0DataRank · unranked

13 citations

Arish Noor, Mahati Paravathaneni, Ibrahim Yassine, Sandra J. Lee, Megan Othus +7 more

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps9603

N/A

0DataRank · unranked

7 citations

James Moon, Yana G. Najjar, Rupesh Kotecha, Vadim Spektor, Michael C. Wu +6 more

Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

(2023)10.1158/2159-8290.c.6549583.v1

N/A

0DataRank · unranked

0 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

S1801: A randomized phase II trial of adjuvant versus neoadjuvant pembrolizumab (PEM) for melanoma.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps10090

N/A

0DataRank · unranked

1 citations

Megan Othus, James Moon, Michael T. Tetzlaff, Elizabeth I. Buchbinder, Vernon K. Sondak +8 more

Association of prior immune checkpoint blockade (ICB) with longer progression-free survival (PFS) in patients treated with intermittent versus continuous dabrafenib and trametinib: A post-hoc analysis of S1320.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10039

N/A

0DataRank · unranked

1 citations

Megan Othus, Adil Daud, Janice M. Mehnert, Thach‐Giao Truong, Robert M. Conry +15 more

Clinical outcomes in patients with BRAFV600 mutant melanoma and undetectable circulating tumor DNA treated with dabrafenib and trametinib.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10059

N/A

0DataRank · unranked

0 citations

Megan Othus, Benjamin Newell Voorhies, Kari Kendra, Shaker R. Dakhil, Amy Harker-Murray +6 more